Get the Stockscreener App
10.65
3.36%
-0.37
After Hours:
10.59
-0.06
-0.56%
Indivior Plc stock is traded at $10.65, with a volume of 738.31K.
It is down -3.36% in the last 24 hours and down -11.03% over the past month.
Indivior PLC is a specialty and generic drug manufacturing company. The company is focused on the development, manufacture, and sale of prescription drugs for treatment of substance use disorders and other serious mental illnesses. Its products include, Sublocade, Perseris, Suboxone, Opvee among others. The vast majority of Indivior's revenue is generated in the United States, followed by United Kingdom and the rest of the world.
See More
Previous Close:
$11.02
Open:
$10.395
24h Volume:
738.31K
Relative Volume:
1.24
Market Cap:
$1.34B
Revenue:
$1.12B
Net Income/Loss:
$5.00M
P/E Ratio:
1,065.00
EPS:
0.01
Net Cash Flow:
$-383.00M
1W Performance:
-12.70%
1M Performance:
-11.03%
6M Performance:
-21.23%
1Y Performance:
-41.74%
1-Day Range:
$10.36
$10.80
1-Week Range:
$10.36
$12.17
52-Week Range:
$7.33
$23.22
Indivior Plc Stock (INDV) Company Profile
Compare INDV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INDV
Indivior Plc
|
10.65 | 1.34B | 1.12B | 5.00M | -383.00M | 0.01 |
|
ZTS
Zoetis Inc
|
174.12 | 78.56B | 9.15B | 2.43B | 2.31B | 5.32 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.61 | 43.15B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
9.51 | 43.00B | 14.26B | 1.55B | 0 | 0.3383 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.29 | 19.59B | 16.54B | -1.64B | 749.00M | -1.45 |
|
NBIX
Neurocrine Biosciences Inc
|
150.51 | 15.24B | 2.24B | 385.90M | 440.10M | 3.73 |
Indivior Plc Stock (INDV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Jul-23-24 | Initiated | Piper Sandler | Overweight |
| Apr-03-24 | Initiated | Craig Hallum | Buy |
| Jul-13-23 | Initiated | Northland Capital | Outperform |
Indivior Plc Stock (INDV) Latest News
(INDV) Technical Pivots with Risk Controls - Stock Traders Daily
China Universal Asset Management Co. Ltd. Makes New Investment in Indivior PLC (NASDAQ:INDV) - MarketBeat
Goldman Sachs Group Inc. Acquires Additional Shares in Indivior PLC - GuruFocus.com
Indivior (NASDAQ:INDV) Shares Down 4.7%Here's Why - MarketBeat
INDV INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Indivior PLC Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Indivior PLC (INDV) Stock Price Down 3.68% on Feb 5 - GuruFocus.com
Indivior to release Q4 and full-year 2024 results on Feb 20 - MSN
FINAL REMINDER INDV DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Indivior PLC Investors to Participate in the Class Action Lawsuit! - ACCESS Newswire
Indivior to release Q4 and full-year 2024 results on Feb 20 By Investing.com - Investing.com South Africa
Indivior to Present Q4 and FY 2024 Financial Results - TipRanks
Indivior Executes Share Repurchase Program, Cancels Over 200,000 Shares - TipRanks
Indivior Completes $100M Share Repurchase Program - TipRanks
Indivior PLC announces new board member - MSN
Indivior PLC announces new board member By Investing.com - Investing.com Australia
Indivior PLC Updates Total Voting Rights - TipRanks
Indivior Strengthens Board with New Appointment - TipRanks
Indivior (NASDAQ:INDV) Rating Increased to Strong-Buy at RODMAN&RENSHAW - MarketBeat
Indivior (LON:INDV) Stock Price Crosses Above Fifty Day Moving AverageTime to Sell? - MarketBeat
Indivior (NASDAQ:INDV) Now Covered by Analysts at Rodman & Renshaw - MarketBeat
Here’s Summers Value Partners’ Investment Thesis for Indivior (INDV) - Insider Monkey
Indivior (NASDAQ:INDV) Raised to Strong-Buy at RODMAN&RENSHAW - Defense World
Indivior names Dr. David Wheadon as new board chair By Investing.com - Investing.com South Africa
Indivior names Dr. David Wheadon as new board chair - MSN
Rodman & Renshaw sets $16 target on Indivior stock with Buy rating - Investing.com Australia
Indivior PLC Announces New Chair of the Board Amid Strategic Leadership Moves - TipRanks
Dr. David Wheadon appointed Chair of the Board - ShareCast
INDV Stockholders Have Opportunity to Lead Indivior PLC Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
Rodman & Renshaw sets $16 target on Indivior stock with Buy rating By Investing.com - Investing.com South Africa
Indivior (LON:INDV) Stock Crosses Above 50 Day Moving Average – What’s Next? - Defense World
Morgan Stanley’s Stake in Indivior Falls Below 5% Threshold - TipRanks
Indivior Advances Share Repurchase Program - TipRanks
Indivior PLC Advances $100 Million Share Repurchase Initiative - TipRanks
Indivior PLC Experiences Change in Voting Rights with Morgan Stanley Acquisition - TipRanks
How to Take Advantage of moves in (INDV) - Stock Traders Daily
Securities Class Actions Down But Not Out After Suboxone - Law360
Reckitt Investors Lose Bid For Opioid Representative Claim - Law360
Indivior (NASDAQ:INDV) Shares Gap DownTime to Sell? - MarketBeat
Indivior (NASDAQ:INDV) Shares Gap UpStill a Buy? - MarketBeat
Following a 23% decline over last year, recent gains may please Indivior PLC (LON:INDV) institutional owners - Simply Wall St
Indivior Executes Share Repurchase to Enhance Shareholder Value - TipRanks
Great week for Indivior PLC (LON:INDV) institutional investors after losing 23% over the previous year - Yahoo Finance
Indivior PLC (NASDAQ:INDV) Short Interest Up 9.9% in December - MarketBeat
Indivior Plc Stock (INDV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.25%
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):